NCT04671901终止2 期
A Single Arm Open-Label Pilot Study of Prophylactic Romiplostim Use Compared to Benchmark Rate in the Prevention of Chemotherapy Induced Thrombocytopenia in Pediatric Solid Tumors Patients Undergoing Myelosuppressive Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 7
- 主要终点
- Total Number of Platelet Transfusions During the Studied Portions of the EFT or D9803 Cycles
研究概览
简要总结
The purpose of this study is to find out whether romiplostim can help prevent low platelet counts caused by N8 or EFT chemotherapy, reduce the number of platelet transfusions required during chemotherapy, and prevent treatment delays due to low platelet counts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of a primary solid tumor. Patients must have histological verification of malignancy at MSKCC.
- •Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP, D
- •Prior to enrollment patient could have been undergoing induction therapy with a similarly myelosuppressive regimen as long as they will be continuing with EFT, MAP, D9803 at the time of study enrollment.
- •Patients undergoing treatment with MAP chemotherapy w ho have had ≥ 1 platelet transfusion during induction stage of treatment.
- •Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit of normal (ULN) for age and ALT/AST ≤ 3 times institutional ULN for age.
- •Normal cardiac function:
- •Shortening fraction greater than or equal to 28% by echocardiogram OR Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium- 99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram.
- •Screening ECG with corrected QT (QTc) interval of < 470 msec.
- •Timing of cardiac assessment: We will utilize the most recent EKG/ECHO when assessing cardiac function. See section 9.0 for additional details.
- •Adequate renal function, defined as an estimated Creatinine Clearance or GFR >40ml/min or an normal creatine for age (see below)
- •Serum Creatinine by age:
- •Age (years) <6: Maximum Serum Creatinine (mg/dL), Male 0.8, Female 0.8 Age (years) 6 to <10: Maximum Serum Creatinine (mg/dL), Male 1, Female 1 Age (years) 10 to <13: Maximum Serum Creatinine (mg/dL), Male 1.2, Female 1.2 Age (years) 13 to <16: Maximum Serum Creatinine (mg/dL), Male 1.5, Female 1.4 Age (years) >16: Maximum Serum Creatinine (mg/dL), Male 1.7, Female 1.4
- •These threshold creatine values were derived from the Scwartz formula estimating GFR, utilizing child length and statured published by the CDC.
排除标准
- •Patients with history of hematologic malignancies or allogenic/autogenic stem cell transplant.
- •Patients with a currently known predisposition to a myeloid stem cell disorder, myeloid leukemia, and/or bone marrow failure syndrome including, but not limited to:
- •Aplastic anemia
- •Ataxia telangiectasia
- •Bloom syndrome
- •Congenital amegakaryocytic thrombocytopenia
- •Cyclic neutropenia
- •Diamond Blackfan anemia
- •Dyskeratosis congenita
- •Familial AML/MDS syndromes (including ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72)
- •Fanconi anemia
- •Kostmann disease
- •Li-Fraumeni syndrome
- •Neurofibromatosis
- •Nijmegen breakage syndrome
- •Noonan syndrome
- •Paroxysmal nocturnal hemoglobinuria
- •Pearson syndrome
- •Poland syndrome
- •Rothmund-Thomson syndrome
- •Severe congenital neutropenia
- •Thrombocytopenia absent radii syndrome
- •Trisomy 8
- •Trisomy 21
- •WHIM syndrome
- •Wiskott Aldrich syndrome
- •Xeroderma pigmentosa
- •Secondary malignancy in the past 5 years.
- •Patients who have previously undergone up-front chemotherapy and have relapsed or progressed through therapy.
- •Patients who have received 4 or more cycles of induction chemotherapy for their current malignancy prior to time of enrollment.
- •Previous use of romiplostim, eltrombopag, recombinant human TPO, or any other TPO receptor agonist, or any investigational platelet producing agent.
- •Patients receiving other investigational agents are not eligible for study entry.
- •History of uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, active heart failure or pericardial disease.
- •Patients with current or prior venous thrombotic event or arterial thrombotic event at time of enrollment will be ineligible for this study.
- •Pregnant women/lactating mothers.
- •Patients unwilling to use effective contraception method, which includes abstinence.
- •Patients with an inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
研究组 & 干预措施
Pediatric Participants
Experimental
Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.
干预措施: Romiplostim (Drug)
结局指标
主要结局
Total Number of Platelet Transfusions During the Studied Portions of the EFT or D9803 Cycles
时间窗: up to 6 months
The primary purpose of this study is to evaluate whether romiplostim administration can decrease the total number of platelet transfusions required during the treatment courses of EFT or D9803 when compared to the benchmark rate.
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerNon-Hodgkin LymphomaHDT-AHCTMultiple MyelomaHodgkin LymphomaNCT04478123Memorial Sloan Kettering Cancer Center62
已完成
2 期
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With LymphomaLymphoma PatientsThrombocytopeniaNCT04673266Memorial Sloan Kettering Cancer Center11
终止
2 期
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyRefractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple MyelomaThrombocytopeniaNCT01676961NYU Langone Health5
已完成
2 期
Study of Romiplostim for Chemotherapy Induced ThrombocytopeniaIsolated Chemotherapy-induced ThrombocytopeniaNCT02052882Memorial Sloan Kettering Cancer Center60
撤回
2 期
Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL InjuryACL - Anterior Cruciate Ligament RuptureACL InjuryNCT03389685NYU Langone Health